MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Net Income 2011-2026 | ONVO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.49 M | -14.7 M | -17.3 M | -16.8 M | -18.7 M | -26.6 M | -34.8 M | -38.4 M | -38.6 M | -30.1 M | -25.8 M | -16.1 M | -43.6 M | -148 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -148 K | -43.6 M | -23.2 M |
Quarterly Net Income Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.69 M | -2.54 M | -2.84 M | - | -3.45 M | -2.55 M | -3.34 M | - | -3.6 M | -3.99 M | -4.03 M | - | -3.26 M | -3.32 M | -3.22 M | - | -3.5 M | -9.54 M | -2.53 M | -2.53 M | -2.51 M | -2.51 M | -8.95 M | -2.77 M | -3.37 M | -3.37 M | -6.29 M | -6.32 M | -6.4 M | -6.4 M | -5.84 M | -7.45 M | -7.79 M | -9.46 M | -10.1 M | -10.7 M | -9.58 M | -9.58 M | -9.44 M | -8.77 M | -10.5 M | -10.5 M | -11.3 M | -8.49 M | -6.99 M | -6.99 M | -8.86 M | -6.43 M | -5.21 M | -19.4 M | -14.2 M | -16.1 M | -9.56 M | -6.47 M | -43.6 M | -37.1 M | -43.5 K | -4.38 M | -67 K | -4.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -43.5 K | -43.6 M | -7.59 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.21 B | $ 110.28 | -2.82 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
77.9 M | $ 13.21 | -2.44 % | $ 3.75 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 14.31 | -2.02 % | $ 1.86 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.41 | -11.3 % | $ 177 M |  China |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
22.7 M | $ 9.03 | -2.48 % | $ 602 M | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
836 M | $ 62.84 | -4.93 % | $ 24.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 15.54 | -5.13 % | $ 470 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-416 M | $ 84.0 | -4.65 % | $ 10.5 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 24.0 | -2.83 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 158.89 | -3.78 % | $ 7.88 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 195.64 | -1.27 % | $ 21.7 B | USA |
 |
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 8.45 | - | $ 33.7 M | Israel |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 102.3 | -0.76 % | $ 8.44 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.06 B | $ 561.97 | -1.98 % | $ 45.2 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-1.22 B | $ 117.62 | -5.45 % | $ 18.7 B | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
6.7 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 452.91 | -2.94 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 233.1 | -2.91 % | $ 25.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.38 | -5.19 % | $ 406 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 4.26 | -7.19 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 7.35 | -5.28 % | $ 942 M | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 164.54 | -2.87 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.2 | -0.95 % | $ 385 M | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
-548 M | $ 184.45 | -5.96 % | $ 18.2 B | USA |
 |
OPKO Health
OPK
|
14 M | $ 1.15 | -1.79 % | $ 798 M | USA |